GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlaxoSmithKline (GSK) is conducting a long-term extension study titled ‘AtDvance’ to assess the safety and efficacy of GSK1070806 in individuals with moderate to severe atopic dermatitis. This study follows participants who completed the phase 2b parent study, aiming to provide insights into the long-term effects of the treatment.
The study tests various doses of GSK1070806, a drug designed to manage symptoms of atopic dermatitis. The intervention involves four experimental groups, each receiving a different dose of the drug.
The study employs a non-randomized, parallel intervention model with double masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish the drug’s long-term safety and efficacy.
Key dates include the actual start date on June 5, 2024, and the last update on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates.
This study update could influence GSK’s stock performance by showcasing potential advancements in dermatological treatments. Investors may view this as a positive development, especially in comparison to competitors in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.